# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Deutsche Bank analyst Scott Deuschle maintains BWX Technologies (NYSE:BWXT) with a Buy and raises the price target from $112...
BWX Technologies (NYSE:BWXT) reported quarterly earnings of $0.82 per share which beat the analyst consensus estimate of $0.75 ...
Barclays analyst David Strauss downgrades BWX Technologies (NYSE:BWXT) from Equal-Weight to Underweight and raises the price...
Actinium-225 (Ac-225) is a critical medical isotope used to kill cancer cells while minimizing the impact to healthy tissues.
BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE:BWXT) and NorthStar Medical Radioisotopes, LLC (NorthStar) toda...